Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR8 | P51685 | 6/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.43 |
| ▸ | NAMPT | P43490 | 3/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.37 |
| ▸ | USP2 | O75604 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | CASP1 | P29466 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | GSK3A | P49840 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2844974 | 0.84 | L3MBTL1 (0.58) | CCR8KCNH2L3MBTL1CYP2C9USP2 | |
| SCHEMBL2849785 | 0.83 | CYP3A4 (0.51) | CYP2C9USP2HSD17B10CYP1A2CYP3A4 | |
| SCHEMBL2844955 | 0.79 | CYP3A4 (0.33) | L3MBTL1CYP2C9USP2HSD17B10CASP1 | |
| SCHEMBL2841817 | 0.79 | NAMPT (0.38) | NAMPTL3MBTL1CYP2C9USP2HSD17B10 | |
| SCHEMBL2847866 | 0.79 | VNN1 (0.40) | CYP2C9HSD17B10CYP3A4CYP2C19ALDH1A1 | |
| SCHEMBL2842376 | 0.76 | CHRM2 (0.51) | L3MBTL1CYP2C9CYP3A4CYP2C19ALDH1A1 | |
| SCHEMBL2846197 | 0.76 | CRBN (0.52) | CYP2C9USP2CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL2840337 | 0.75 | HTT (0.39) | NAMPT | |
| SCHEMBL2842730 | 0.75 | SPR (0.56) | KCNH2L3MBTL1CYP2C9HSD17B10CYP1A2 | |
| SCHEMBL2842491 | 0.74 | GABRD (0.40) | NAMPTCYP2C9HSD17B10CYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3344231-A1 | STABILIZED GLUCAGON SOLUTIONS | Latitude Pharmaceuticals, Inc. (US) | 2018-07-11 | — | — | EP | disclosed |
| EP-2444120-B1 | Spirocyclic amiloride analogues as ENac blockers | NOVARTIS AG (CH) | 2017-09-27 | — | — | EP | disclosed |
| US-9643983-B2 | Treating diseases mediated by blockade of the epithelial sodium channel with pyrazine-2-carboxamide derivatives | NOVARTIS AG (CH) | 2017-05-09 | — | — | US | disclosed |
| WO-2017040928-A1 | STABILIZED GLUCAGON SOLUTIONS | LATITUDE PHARMACEUTICALS, INC. (US) | 2017-03-09 | — | — | WO | disclosed |
| US-20160068546-A1 | TREATING DISEASES MEDIATED BY BLOCKADE OF THE EPITHELIAL SODIUM CHANNEL WITH PYRAZINE-2-CARBOXAMIDE DERIVATIVES | NOVARTIS AG (CH) | 2016-03-10 | — | — | US | disclosed |
| US-9139586-B2 | Treating diseases mediated by blockade of the epithelial sodium channel with pyrazine-2-carboxamide derivatives | NOVARTIS AG (CH) | 2015-09-22 | — | — | US | disclosed |
| US-20150231142-A1 | Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases | VERTEX PHARMA (US) | 2015-08-20 | — | — | US | disclosed |
| US-20150150879-A2 | Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases | VERTEX PHARMACEUTICALS INCORPORATED | 2015-06-04 | — | — | US | disclosed |
| EP-2813227-A1 | Compositions for treatment of cystic fibrosis and other chronic diseases | Vertex Pharmaceuticals Incorporated (US) | 2014-12-17 | — | — | EP | disclosed |
| US-20140329814-A2 | Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases | VERTEX PHARMA (US) | 2014-11-06 | — | — | US | disclosed |
| US-20140171421-A1 | TREATING DISEASES MEDIATED BY BLOCKADE OF THE EPITHELIAL SODIUM CHANNEL WITH PYRAZINE-2-CARBOXAMIDE DERIVATIVES | NOVARTIS AG (CH) | 2014-06-19 | — | — | US | disclosed |
| US-20140121208-A1 | Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-05-01 | — | — | US | disclosed |
| US-8697687-B2 | Treating diseases mediated by blockade of the epithelial sodium channel with pyrazine-2-carboxamide derivatives | NOVARTIS AG (CH) | 2014-04-15 | — | — | US | disclosed |
| US-20130012500-A1 | ORGANIC COMPOUNDS | BHALAY GURDIP (GB) | 2013-01-10 | — | — | US | disclosed |
| EP-2520574-A1 | Amiloride analogues substituted on the cyclic guanidine moiety as ENaC blockers for treating respiratory diseases | Novartis AG (CH) | 2012-11-07 | — | — | EP | disclosed |
| EP-2490708-A2 | STABILIZED GLUCAGON SOLUTIONS | Biodel, Inc. (US) | 2012-08-29 | — | — | EP | disclosed |
| EP-2231280-A2 | ORGANIC COMPOUNDS | Novartis AG (CH) | 2010-09-29 | — | — | EP | disclosed |
| US-20100130506-A1 | Organic Compounds | NOVARTIS AG | 2010-05-27 | — | — | US | disclosed |
| WO-2009074575-A2 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130012500-A1 | ORGANIC COMPOUNDS | OR10J3, REN, CACNA1E | CCR8 1001/4885KCNH2 31/4885NAMPT 4474/4885 |
| US-20140329814-A2 | Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases | CFTR, SLC26A4, ABCB11 | CCR8 1671/4885KCNH2 99/4885NAMPT 2132/4885 |
| US-20160068546-A1 | TREATING DISEASES MEDIATED BY BLOCKADE OF THE EPITHELIAL SODIUM CHANNEL WITH PYRAZINE-2-CARBOXAMIDE DERIVATIVES | SCNN1B, SCNN1A, SCNN1G | CCR8 3041/4885KCNH2 20/4885NAMPT 3224/4885 |
| US-20140121208-A1 | Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases | CFTR, SLC26A4, ABCB11 | CCR8 1671/4885KCNH2 99/4885NAMPT 2132/4885 |
| US-20150231142-A1 | Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases | CFTR, SLC26A4, ABCB11 | CCR8 1671/4885KCNH2 99/4885NAMPT 2132/4885 |
| US-20100130506-A1 | Organic Compounds | OR10J3, REN, CACNA1E | CCR8 1001/4885KCNH2 31/4885NAMPT 4474/4885 |
| US-20150150879-A2 | Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases | CFTR, SLC26A4, ABCB11 | CCR8 1671/4885KCNH2 99/4885NAMPT 2132/4885 |
| US-20140171421-A1 | TREATING DISEASES MEDIATED BY BLOCKADE OF THE EPITHELIAL SODIUM CHANNEL WITH PYRAZINE-2-CARBOXAMIDE DERIVATIVES | SCNN1B, SCNN1A, SCNN1G | CCR8 3041/4885KCNH2 20/4885NAMPT 3224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.